TSHA TAYSHA GENE THERAPIES INC revenue, earnings and financials
For the quarter ended June 30, 2026, TAYSHA GENE THERAPIES INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$46.6M and diluted EPS of −$0.13; over the last four quarters revenue was $5.49M and net income −$150M; for the fiscal year ended December 2025 revenue was $9.77M, up 17.3% on the year before.
TSHA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $9.77M, gross profit n/a, operating income −$110M, net income −$109M (margin -1115.3%), EPS −$0.34
- Fiscal year ended Dec 2024: revenue $8.33M, gross profit n/a, operating income −$91.5M, net income −$89.3M (margin -1071.6%), EPS −$0.36
- Fiscal year ended Dec 2023: revenue $15.5M, gross profit n/a, operating income −$72.4M, net income −$112M (margin -722.1%), EPS −$0.96
- Fiscal year ended Dec 2022: revenue $2.50M, gross profit n/a, operating income −$162M, net income −$166M (margin -6635.3%), EPS −$3.78
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$173M, net income −$175M (margin n/a), EPS −$4.64
TSHA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$46.6M, EPS −$0.13
- Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$42.4M, EPS −$0.12
- Quarter ended Dec 31, 2025 (from the annual report): revenue $5.49M (up 171.3% year over year), net income −$27.9M, EPS −$0.08
- Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$32.7M, EPS −$0.09
- Quarter ended Jun 30, 2025: revenue $1.99M (up 78.6% year over year), net income −$26.9M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue $2.30M (down 32.5% year over year), net income −$21.5M, EPS −$0.08
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.02M (down 43.9% year over year), net income −$18.8M, EPS −$0.07
- Quarter ended Sep 30, 2024: revenue $1.79M (down 62.3% year over year), net income −$25.5M, EPS −$0.10
- Quarter ended Jun 30, 2024: revenue $1.11M (down 53.6% year over year), net income −$20.9M, EPS −$0.09
- Quarter ended Mar 31, 2024: revenue $3.41M (down 27.5% year over year), net income −$24.1M, EPS −$0.10
- Quarter ended Dec 31, 2023 (from the annual report): revenue $3.60M, net income $47.7M, EPS $0.63
- Quarter ended Sep 30, 2023: revenue $4.75M, net income −$117M, EPS −$0.93
- Quarter ended Jun 30, 2023: revenue $2.40M, net income −$24.6M, EPS −$0.38
- Quarter ended Mar 31, 2023: revenue $4.71M, net income −$17.6M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$55.1M, EPS −$0.96
- Quarter ended Sep 30, 2022: revenue n/a, net income −$26.5M, EPS −$0.65
- Quarter ended Jun 30, 2022: revenue n/a, net income −$34.1M, EPS −$0.85
- Quarter ended Mar 31, 2022: revenue n/a, net income −$50.3M, EPS −$1.32
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$50.4M, EPS −$1.33
- Quarter ended Sep 30, 2021: revenue n/a, net income −$51.2M, EPS −$1.35
TSHA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$93.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$81.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$73.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$88.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$117M, share buybacks n/a
TSHA balance sheet
- Jun 30, 2026: cash $455M, total assets $470M, total liabilities $83.2M, shareholders' equity $387M, long-term debt $49.3M
- Mar 31, 2026: cash $277M, total assets $300M, total liabilities $88.4M, shareholders' equity $212M, long-term debt $49.0M
- Dec 31, 2025: cash $320M, total assets $343M, total liabilities $96.4M, shareholders' equity $247M, long-term debt $50.1M
- Sep 30, 2025: cash $297M, total assets $317M, total liabilities $97.6M, shareholders' equity $219M, long-term debt $50.9M
- Jun 30, 2025: cash $313M, total assets $333M, total liabilities $84.6M, shareholders' equity $249M, long-term debt $41.1M
- Mar 31, 2025: cash $117M, total assets $138M, total liabilities $83.3M, shareholders' equity $55.1M, long-term debt $42.5M
- Dec 31, 2024: cash $139M, total assets $160M, total liabilities $88.8M, shareholders' equity $71.5M, long-term debt $43.9M
- Sep 30, 2024: cash $158M, total assets $180M, total liabilities $91.4M, shareholders' equity $88.8M, long-term debt $43.0M
What is TSHA's revenue?
TAYSHA GENE THERAPIES INC reported $5.49M of revenue over its last four quarters, through June 30, 2026.
Is TSHA profitable?
No. TAYSHA GENE THERAPIES INC lost $150M over the last four quarters.
What is TSHA's EPS?
Diluted earnings per share over the last four quarters were −$0.42; −$0.13 in the latest quarter.